More patients with metabolic syndrome received a renin–angiotensin–aldosterone system (RAAS) inhibitor or a statin than those without metabolic syndrome (for RAAS inhibitors: 63.2% vs. 14.3%, p = 0.017; for statin: 63.2% vs. 0%, p = 0.002). This evidence concerns the gene REN and metabolic syndrome.